ImmunityBio, Inc. (IBRX)
ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy
ImmunityBio offers a best-in-class, approved immunotherapy, ANKTIVA, driving rapid revenue growth and significant market share in NMIBC. IBRX's pipeline is robust, with multiple Phase 1-3 trials targeting NSCLC, glioblastoma, HIV, and other high-value indications, supporting long-term upside. The recent 40% pullback from 52-week highs creates an attractive entry point, with strong balance sheet support and no immediate financial risks.
ImmunityBio: A Long-Term Bull Case Worth Watching
ImmunityBio is pivoting from a single-product Anktiva focus to a broad immunotherapy platform, emphasizing memory-like cytokine-enriched NK cells (M-ceNK). Key near-term catalysts include the pivotal QUILT-2.005 bladder cancer trial, lymphopenia indication expansion, and the glioblastoma (GBM) program, each validating the immune-restoration thesis. IBRX trades at a significant premium (65x trailing sales, 44x forward sales), reflecting high expectations for Anktiva's transition to first-line therapies and broader platform validation.
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?
ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
IBRX and the BCG Shortage: Deals That Could Expand Demand
ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.
ImmunityBio: Anktiva Explained and What Comes Next
IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.
IBRX Stock Outlook After Q1 Results and a New FDA Review
ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.
ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout
ImmunityBio is transitioning into a scalable bladder cancer immunotherapy platform, driven by accelerating Anktiva adoption and robust revenue growth. 1Q26 revenue surged 168% YoY to $44.2M, with strong physician uptake, but operating expenses and adjusted net loss ($86.2M) remain elevated amid heavy investment. The papillary sBLA for Anktiva is a key near-term catalyst; regulatory uncertainty persists, but compelling QUILT-3.032 data and prior FDA approval in CIS support optimism.
FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer Therapy
ImmunityBio's shares rise after the FDA accepts a filing to expand Anktiva's use in bladder cancer, with a decision due by January 2027.
ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder Cancer
IBRX secures five U.S. patents for Anktiva in bladder cancer, extending franchise protection through 2035 amid strong sales growth.
ImmunityBio: Looking Beyond Bladder Cancer To A Multibillion-Dollar Solid Tumor TAM
ImmunityBio, Inc. receives a Strong Buy rating, driven by ANKTIVA's compelling clinical data and major regulatory catalysts ahead. ANKTIVA's unique IL-15 mechanism boosts lymphocyte proliferation, showing strong efficacy in solid cancers with lymphopenia and outperforming prior immunotherapies. QUILT trial results validate lymphocyte count as a survival biomarker, supporting likely BLA approval and unlocking broad oncology opportunities.
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.15 per share a year ago.
IBRX Global Rollout: EU, MENA, and Asia Shape 2026-27 Catalysts
ImmunityBio's global push spans EU, MENA, and Asia, with early Saudi sales and key 2026 data readouts set to test demand and drive next growth phase.
